SCT510

DRUG3 trials

Sponsors

Sinocelltech Ltd., First Affiliated Hospital of Zhejiang University

Conditions

HealthyHepatocellular CarcinomaNon-squamous Cell Non-small Cell Lung Cancer

Phase 1

PK and Safety of SCT510

CompletedNCT05113511

First Affiliated Hospital of Zhejiang UniversityHealthy

Start: 2018-05-09End: 2021-07-26Updated: 2021-11-09

Phase 2

SCT-I10A Plus SCT510 Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular Carcinoma

Active, not recruitingNCT04560894

Sinocelltech Ltd.Hepatocellular Carcinoma

Start: 2020-11-11End: 2024-09-30Updated: 2024-02-01

Phase 3

To Evaluate the Efficacy and Safety of SCT510 in the Treatment of Non-small Cell Lung Cancer

Sinocelltech Ltd.Non-squamous Cell Non-small Cell Lung Cancer

Start: 2019-02-28End: 2022-01-31Target: 560Updated: 2019-01-03

Related Papers

Population Pharmacokinetics of SCT510 (a Bevacizumab Biosimilar) and Avastin<sup>®</sup> in Healthy Subjects and Patients with Non-squamous Non-small Cell Lung Cancer.

2026-01-06

Finotonlimab (PD-1 inhibitor) plus bevacizumab (bevacizumab biosimilar) as first-tier therapy for late-stage hepatocellular carcinoma: a randomized phase 2/3 trial.

2025-08-062 citations

Efficacy and Safety of Biosimilar SCT510 Compared with Bevacizumab for the First-Line Treatment of Advanced Non-Squamous Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Phase III Study.

2024-09-04

SCT-I10A combined with a bevacizumab biosimilar (SCT510) versus sorafenib in the first-line treatment of advanced hepatocellular carcinoma: A randomized phase 3 trial.

Journal of Clinical Oncology2024-06-0112 citations

A Randomized, Double-Blind, Parallel-Controlled Phase I Study Comparing the Pharmacokinetics, Safety, and Immunogenicity of SCT510 to Bevacizumab (Avastin<sup>®</sup>) in Healthy Chinese Males.

2023-05-294 citations